clinical trial · NCT07393373
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
QED Therapeutics, a BridgeBio company·phase2·enrolling by invitation·n = 135
HypochondroplasiaInfigratinib
brief summary
Phase 2, multicenter, OLE study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR (fibroblast growth factor receptor) 1-3-selective tyrosine kinase inhibitor, in participants with Hypochondroplasia (HCH) who previously completed ACCEL 2/3, and potentially additional participants who completed ACCEL. Participants rolling over directly from the observational ACCEL study must have had at least a 6-month period of growth assessment in that study.
started
Apr 21, 2026
primary completion
May 31, 2036
completion
May 31, 2036
last updated
Feb 6, 2026
official title
Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Hypochondroplasia: ACCEL OLE
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol